Oddity, the parent company of Il Makiage and SpoiledChild, raised its full-year forecast as it shrugged off concerns over the economic backdrop.

It now expects net revenue between $235 million and $239 million, representing year-over-year growth between 22 percent and 24 percent. Adjusted diluted earnings per share is expected between 85 cents and 89 cents. 

“Our Q125 results exceeded our expectations across all metrics and allow us to raise our full-year outlook. We delivered an outstanding result for our biggest quarter of the year, setting us up to overdeliver on our financial algorithm in 2025,” said Oran Holtzman, Oddity cofounder and CEO. 

For the first quarter, net revenue was $268 million compared to $212 million in the first quarter of 2024. Net income was $38 million, up from $33 million a year earlier. Adjusted diluted EPS were 69 cents, compared to 61 cents.

“We are pleased with our financial results for the first quarter, which beat our guidance across revenue, gross margin, adjusted [earnings before interest, taxes, depreciation and amortization], and adjusted EPS,” said Lindsay Drucker Mann, Oddity global chief financial officer. “These excellent Q125 results, combined with a strong start to Q2, our sustained high repeat rates, the resilience of our category, and our agile business model allow us to continue investing in our growth while raising our full-year outlook.”

Asked about tariffs, she called the impact “very manageable.”

“We have some exposure, but it’s really small in the scheme of things. That’s why, even as we incorporated tariffs into our guidance, we actually raised our gross margin guidance for the full year from 70 to 71 percent, as well as raising our full-year EBITDA guidance. So we’re in a strong position, because we already have high gross margins, which makes us just overall more insulated. We have a flexible global supply chain, and we also have a number of other efficiencies that we have already been delivering on, independent of tariffs.”

Oddity is gearing up to soft-launch brand three, a telehealth platform for consumers with medical-grade skin and body issues, in the third quarter. It will be a mix of over-the-counter and prescription. Brand four will follow shortly after.